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Abstract
Background: Previous studies have demonstrated therapeutic benefits of slow breathing (SLOWB) in 
chronic heart failure (HF) but its impact on cardiovascular reactivity in response to laboratory stressors 
remains unknown. 
Methods: Using device-guided breathing this study explored the acute and long-term effects of SLOWB 
on hemodynamic responses to handgrip, mental and cold pressor tests, and health-related quality of life 
(QoL) in stable HF patients with reduced ejection fraction (HFrEF) who had received all available opti-
mal drug and device therapies. Blood pressure (BP) and heart rate (HR) were measured in 21 patients 
with HFrEF (23.9 ± 5.9%) at rest, during laboratory stressors, before and after acute SLOWB, and  
12 weeks after SLOWB home training (30 min daily). Health-related QoL (MacNew questionaries) was 
assessed before and 12 weeks after SLOWB home training. 
Results: Resting BP significantly increased in response to three laboratory stressors. Pressor and car-
diac changes during mental stress were greater than responses to the handgrip test (p < 0.05). Mental 
stress also produced a greater HR change than cold pressor test (p < 0.05). Both acute and long-term 
SLOWB significantly reduced BP and HR responses to mental stress (p < 0.05), but not to isometric 
and cold pressor tests. SLOWB improved scores of all domains of QoL (p < 0.05) at 12 weeks follow-up. 
Conclusions: These findings demonstrate that SLOWB reduces acute and chronic effects of cardio-
vascular reactivity to mental stress and improves various aspects of health-related QoL in patients with 
severe HFrEF. Whether stress reduction and psychological changes achieved with SLOWB may translate 
to improved outcomes in HFrEF warrants further exploration. (Cardiol J XXXX; XX, X: xx–xx)
Key words: heart failure with reduced ejection fraction, slow breathing, hemodynamics, 
laboratory stressors, health-related quality of life
Introduction
Chronic heart failure (HF) is considered 
a global pandemic with survival outcomes as malig-
nant as some common cancers [1]. The progression 
of HF, worsening of symptoms and increasingly fre-
quent hospitalizations negatively influence patient 
functional ability and health-related quality of life 
(QoL) [2–5]. Depression is one of the most impor-
tant factors determining QoL in HF patients, this 
also contributes to social isolation [6, 7]. Depressed 
mood and vital exhaustion are strong predictors of 
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low life expectancy, all-cause and cardiovascular 
(CV) mortality, independent of classical risk factors 
[8–12]. Acute emotional stress has been linked to 
a high incidence of acute CV events, arrhythmias 
and sudden cardiac death [13]. Mental stress per se 
is a potent trigger for myocardial ischemia. Chronic 
effects of mental stress and psychological states 
have been reported as important independent pre-
dictors of coronary heart disease, atherosclerosis, 
hypertension and other adverse consequences [13, 
14]. CV responses to mental stress independently 
predicted fatal and non-fatal cardiac and vascular 
events in patients with coronary artery disease 
(CAD) [15, 16]. Furthermore, altered CV reactivity 
to acute mental stress were independently associ-
ated with an increased risk of earlier mortality in 
HF [17].
Despite the disease burden, there are a limited 
number of clinical studies in patients with very se-
vere HF. Given the importance of psychological dis-
tress and poor QoL to the severity of HF, associated 
morbidity and mortality, hospital readmission, and 
duration of hospital stay [2, 4, 18–21], interventions 
to specifically target potentiated reactivity to men-
tal challenges, physical exertion [22], social aspects 
and associated QoL are likely to be of substantial 
clinical benefit. The feasibility and therapeutic 
effectiveness of the slow breathing (SLOWB) 
technique has been documented in chronic HF 
[23–28]. Very recently, it was documented that 
SLOWB home training improves clinical symp-
toms, physical and cardiorespiratory capacity, and 
vagal activity in patients with severe HF with 
reduced ejection fraction (HFrEF) irrespective of 
HF etiology [29]. However, health-related QoL in 
response to SLOWB is less known, demonstrat-
ing an overall improvement without a clear trend 
toward a reduction of any specific component [25] 
or a non-significant tendency toward improved 
QoL [27]. The impact of SLOWB on CV responses 
to laboratory stressors remain unknown in HF. 
Therefore, this study investigated CV reactivity 
to laboratory-induced stressors and whether, and 
to what extent home paced SLOWB may restrain 
hemodynamic responses to challenge stressors 
and improve QoL in patients with severe HFrEF. 
Methods 
Subjects
The study was approved by the Institutional 
Ethics Committee and written informed consent 
was obtained from all patients. This prospective 
study was previously described in detail [29] 
and included a total of 21 non-smoking patients 
(16 males, 5 females) with stable chronic HFrEF 
diagnosed as per European Society of Cardiology 
(ESC) guidelines [4, 30]. Patients were recruited 
from a larger cohort of HF patients following the 
CONSORT guidelines. Only patients who received 
all available treatment options including optimal 
medical drug and device therapies were enrolled. 
All patients were receiving stable doses of optimal 
multi-drug therapy which had been kept unchanged 
for at least 6 weeks prior to study enrolment and 
was maintained (including drugs and dosage) over 
the 3-month study period. 
Study protocol 
Patients were studied at baseline before and 
after acute performance of SLOWB exercise, and 
then at 3 months follow-up of monitored SLOWB 
home training according to the same protocol. 
Measurements of continuous beat-to-beat finger 
blood pressure (BP), heart rate (HR), respiration 
and saturation (ADInstruments, Dual Bio Amp; 
ADInstruments, Ltd., Oxford, UK) were recorded 
in a supine position at rest over a 20-min duration 
followed by an application of two laboratory stress-
ors (i.e. sustained handgrip, mental arithmetic) 
under carefully standardized conditions. Then 
patients performed a SLOWB exercise with the 
use of device-guided breathing (RESPeRATE®) 
for 15 min. Following SLOWB and a 20-min re-
covery period, application of sustained handgrip 
and mental arithmetic tests were repeated. A cold 
pressor test was performed once at the end of the 
study protocol, due to its sustained hemodynamic 
effects. The protocol investigating the impact of 
SLOWB on CV responses to laboratory stressors 
is consistent with a previous study in patients with 
untreated essential hypertension [31]. 
In line with our established protocol [31–33], 
an isometric handgrip test was conducted by 
asking patients to sustain a handgrip of 30% of 
patient maximum voluntary  contraction using 
a dynamometer. Mental stress was performed by 
asking the subject to do serial subtractions as fast 
as possible. Each stress test lasted 3 min with 
a 10-min rest period between tests. Following 
a 10-min recovery period, a cold pressor test was 
performed by immersing the hand into an ice water 
container for 2 min. 
MacNew Health-related Quality of Life 
questionnaire
The MacNew is a self-administered heart 
disease-specific health-related QoL instrument and 
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addresses three major QoL domains: the Emotion-
al, Physical, and Social domains. This instrument 
consists of 27 items, each with a 7-point Likert 
response scale, measuring the 3 inter-related do-
mains of physical activities (13-item), emotional 
(14-item) and social functioning (13-item). There 
are 5 items related to patient symptoms including 
angina, shortness of breath, fatigue, dizziness and 
aching legs. The maximum possible score in any 
domain is 7 and the minimum is 1 with the minimal 
important difference of 0.50 points on the 7-point 
MacNew global scale and each subscale. Domain 
scores are calculated by taking the average of the 
responses to the items in each domain and by aver-
aging all 27 items providing a global health-related 
QoL score. Amongst other conditions, the MacNew 
questionnaire has been validated in HF patients 
[34, 35]. As part of the international HeartQOL 
Study, the MacNew form was translated into Polish 
demonstrating its reliability and validity in patients 
with CAD, myocardial infarction and HF [36, 37]. 
The MacNew questionnaire was completed by 
all patients at baseline and by 16 (76%) participants 
3 months after SLOWB home training. 
Serum biochemistry
Routine blood tests were performed in all pa-
tients at each study visit at the associated Clinical 
Laboratory Centre. 
Slow-breathing technique
A device-guided SLOWB pacing (goal below 10 
breaths per minute) was performed twice daily with 
each session lasting 15 min, through use of an ad 
hoc device RESPeRATE® (Intercure Ltd., Northern 
Industrial Area, Israel) as described previously 
[31]. At the first visit, patients were instructed on 
how to synchronize their breathing with guiding 
tones generated by the RESPeRATE® in response 
to their breathing pattern. Following the comple-
tion of all tests at baseline, all patients received the 
device and a translated training manual on its use 
in a home setting. Performance of SLOWB exercise 
was scheduled for two 15-min daily sessions (in 
total 30 min per day) over the 3 months. Patients 
were asked to breathe effortlessly and gradually 
at home, irrespective of the time of the day, in a 
quiet room and in a comfortable position as recom-
mended in the RESPeRATE® manual. Patients were 
called by an investigator (K.L.) weekly through the 
duration of the study to obtain information stored 
on the device regarding the SLOWB exercise (i.e. 
number of sessions, therapeutic minutes, initial 
breathing, final breathing rate, the ability to syn-
chronize respiratory rate with guiding tones, breath 
detection). Patients were asked to repeat all tests 
after 3 months of SLOWB home exercise.
Statistical analysis 
Results are expressed as means ± standard 
deviation (SD) or percentage (%). Changes in vari-
ables between baseline and 3 month follow-up were 
analyzed using a paired t-test. Analysis was per-
formed on ranks for non-Gaussian data. Statistical 
analysis was performed using SigmaPlot Version 
13.0.0.83 (Systat Software, Inc. Leadtools, Dundas 
Software LTD. Reg. No. 775201235). The sample 
size and power calculation for this patient cohort 
had been published previously [29]. An additional 
analysis revealed that 10 patients would have 80% 
power for a paired t-test in detecting an increase 
in systolic BP (SBP) in response to mental stress 
of 3.4 mmHg at the level of significance 0.05 
and an estimated SD of 3.4. The present study 
revealed that 21 patients with a SD of 3.4 and an 
increase in SBP of 3.4 mmHg had a power of 99.2%. 
A value of p < 0.05 was considered statistically 
significant. 
Results
Patient demographic characteristics are shown 
in Table 1. Twenty-one patients with HFrEF in 
New York Heart Association classes I (n = 5), 
II (n = 13) and III (n = 3) had a mean left ventricu-
lar ejection fraction (LVEF) of 23.9 ± 5.9%, at the 
Table 1. Heart failure (HF) etiology and associa­
ted co­morbidities of the entire study cohort.
Parameter Number (n = 21)
Ischemic HF 9 (43%)
Non­ischemic HF 12 (57%)
Myocardial infarction 8 (38%)
Paroxysmal AF 3 (14%)
Persistent AF 2 (10%)
Arterial hypertension 8 (38%)
Diabetes 5 (24%)
CKD (eGFR < 60 mL/min/1.73 m2) 6 (29%)
PCI 6 (29%)
CABG 3 (14%)
ICD 9 (43%)
CRT­D 7 (33%)
Data expressed as numbers or percentage (%). AF — atrial fibrilla­
tion; CKD — chronic kidney disease; PCI — percutaneous coronary 
intervention; CABG — coronary artery bypass graft; ICD — implant­
able cardioverter­defibrillator; CRT­D — cardiac resynchronization 
therapy defibrillator
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age of 52 ± 17 years and a body mass index (BMI) 
of 28 ± 4 kg/m2. 
Patients were on optimal drug therapy includ-
ing beta-blockers (carvedilol, bisoprolol or meto-
prolol), aldosterone antagonists (spironolactone 
or eplerenone), angiotensin-converting enzyme 
inhibitors (ACEI, quinapril, ramipril, enalapril 
or perindopril). Three patients were receiving 
angiotensin II receptor blockers (valsartan or 
telmisartan) due to intolerance of ACEI. Other 
drugs included amiodarone (n = 5), ivabradine 
(n = 4), trimetazidine (n = 3), furosemide (n = 11), 
torasemide (n = 9), statins (n = 14) (atorvastatin, 
rosuvastatin or simvastatin), acetylsalicylic acid 
(n = 5) and anticoagulants (n = 12) including war-
farin, dabigatran or rivaroxaban. No patients were 
receiving Entresto (sacubitril/valsartan).
Systolic BP and diastolic BP (DBP) signifi-
cantly increased in response to acute exposure to 
handgrip, mental and cold pressor tests at baseline 
visit (Table 2). However, pressor (5.7 ± 4.5 vs. 
3.4 ± 3.4, p < 0.05) and cardiac (4.8 ± 6.0 vs. 
2.5 ± 4.1, p < 0.05) responses to mental stress 
were significantly greater than the handgrip test. 
Mental stress also produced a greater HR change 
than cold pressor test (4.8 ± 6.0 vs. 0.9 ± 4.4, 
p < 0.05) but not in BP (5.7 ± 4.5 vs. 3.5 ± 6.7, 
p = 0.13). A significant rise in HR was observed 
following isometric and arithmetic tests but not 
cold pressor test (Table 2). 
Acute effects of SLOWB on SBP, DBP and HR 
responses to mental and handgrip stress tests are 
demonstrated in Table 3. BP and HR responses to 
isometric handgrip tests were similar before and 
after acute SLOWB (Table 3). 
Acute SLOWB significantly reduced BP and 
HR responses to mental stress (Table 3). 
Long-term SLOWB home training resulted 
in further significant attenuation of BP and HR 
responses to mental tests but had no significant 
impact on hemodynamic responses to handgrip 
and cold pressor tests (Table 3). 
SLOWB home training significantly improved 
physical, mental and social components, and a 
global score in HFrEF (Fig. 1). 
Discussion
The novel finding of the present study is that 
both acute and long-term SLOWB significantly 
diminishes CV effects of mental stress but not 
physical stressors in patients with severe HFrEF. 
This report also documents that, in these HFrEF 
patients, a 3-month SLOWB home training im-
proves subjective health-related QoL in all domains 
including physical, mental, social components and 
a global score. 
Recent reports documenting the effectiveness 
of SLOWB home training in improving oxygen 
saturation, cardiorespiratory capacity, functional 
performance, vagal activity, LVEF and reducing 
pulmonary pressure and breathlessness highlight 
the important role of breathing frequency in HF 
patients [23, 25, 26, 28, 29, 38–40]. 
High sympathetic excitation is a hallmark of 
HF and independent predictor of CV mortality in 
Table 2. Acute cardiovascular reactivity to mental stress, handgrip and cold pressor tests in heart failure 
with reduced ejection fraction patients at baseline. 
Measurements Before test After test D changes P
Handgrip test
SBP [mmHg] 113 ± 7 116 ± 9 3.4 ± 3.4 < 0.001
DBP [mmHg] 88 ± 5 90 ± 6 2.1 ± 2.4 < 0.001
HR [bpm] 64 ± 8 66 ± 6 2.5 ± 4.1 < 0.05
Mental stress
SBP [mmHg] 114 ± 9 119 ± 9 5.7 ± 5.0 < 0.0001
DBP [mmHg] 88 ± 5 92 ± 6 3.2 ± 2.4 < 0.0001
HR [bpm] 65 ± 6 69 ± 8 4.8 ± 6.0 < 0.01
Cold pressor test
SBP [mmHg] 118 ± 10 121 ± 13 3.5 ± 6.7 < 0.01
DBP [mmHg] 90 ± 5 92 ± 7 1.5 ± 2.9 < 0.05
HR [bpm] 64 ± 7 65 ± 7 0.9 ± 4.4 0.39
Data are means ± standard deviation. SBP — systolic blood pressure; DBP — diastolic blood pressure; HR — heart rate
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chronic HF [41–43]. The magnitude of sympathetic 
activation has been directly linked to the severity of 
HF and reduced left ventricle (LV) function [44]. LV 
dysfunction results in several neurohumoral com-
pensatory mechanisms including increases in HR, 
myocardial oxygen demand, ischemia, myocardial 
contractility, peripheral vasoconstriction and blood 
volume to maintain cardiac output and peripheral 
tissue perfusion [45]. However, with further LV 
impairment and HF progression, the compensatory 
regulatory alterations in autonomic control may be 
counter effective, contributing to a depletion of 
myocardial noradrenaline (NA) store and decreased 
myocardial adrenoreceptor density, subsequently 
potentiating stress to cardiac muscle, impairment 
of reactivity to exogenous challenges (i.e. physical 
exertion, fatigue, dyspnoea) and CV responses, 
thereby worsening prognosis. While pharmaco-
logical blockade of neurohumoral hyperactivation 
provides a biological rationale for HF management, 
the increasing number of hospitalizations for HF 
decompensation and associated death suggests the 
necessity for additional treatment options. In this 
context, our recent findings and others of beneficial 
effects of SLOWB home training are likely to be 
associated with breaking or weakening the vicious 
cycle in patients with severe HFrEF [29]. 
Previous studies have demonstrated that 
both exaggerated (likely occurring at an earlier 
stage of disease) and blunted (likely occurring in 
an advanced stage of disease) CV and hormonal 
reactivity to psychological stress bear negative 
prognostic health outcomes [46, 47]. In chronic 
HF (mean LVEF 31.8 ± 6.9%), low DBP and HR 
responses to acute mental stress were indepen-
dently associated with a higher mortality risk [17]. 
In the present study, patients with severe HFrEF 
(mean LVEF 23.9 ± 5.9%) had diminished BP and 
HR reactivity to laboratory stressors compared 
to patients with untreated essential hypertension 
[31]. In patients with severe HFrEF, the magnitude 
Figure 1. Effects of slow breathing (SLOWB) home train­
ing on health­related quality of life changes in physical, 
mental and social domains, and a global score in heart 
failure with reduced ejection fraction (HFrEF) patients at 
3 month follow­up (3 MFU) compared to baseline (BSL).
Table 3. Changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) 
in responses to handgrip and mental stress tests before and after acute effects of slow breathing 
(SLOWB) at baseline, and at 3 month follow­up (3MFU) of SLOWB home training in heart failure with 
reduced ejection fraction patients.
Measurement Before SLOWB  
— baseline
After 
SLOWB
P Before SLOWB 
— 3MFU
After 
SLOWB
P P: baseline  
vs. 3MFU
Handgrip test
D SBP [mmHg] 3.4 ± 3.4 3.0 ± 3.2 0.49 2.5 ± 3.4 2.6 ± 3.1 0.91 0.25
D DBP [mmHg] 2.1 ± 2.4 2.1 ± 2.2 0.38 1.8 ± 2.8 2.7 ± 2.9 0.57 0.52
D HR [bpm] 2.5 ± 4.1 1.8 ± 3.3 0.70 1.0 ± 7.6 4.0 ± 5.4 0.14 0.97
Mental stress
D SBP [mmHg] 5.7 ± 4.5 3.7 ± 3.1 < 0.05 3.4 ± 4.1 1.3 ± 3.4 < 0.05 < 0.05
D DBP [mmHg] 3.2 ± 2.4 2.1 ± 2.1 < 0.01 2.2 ± 2.4 1.5 ± 1.9 0.17 < 0.05
D HR [bpm] 4.8 ± 6.0 2.8 ± 5.9 < 0.05 2.7 ± 5.0 2.2 ± 4.5 0.19 < 0.05
Cold pressor test
D SBP [mmHg] – 3.5 ± 6.7 – – 3.3 ± 5.8 – 0.93
D DBP [mmHg] – 1.5 ± 2.9 – – 1.5 ± 3.1 – 0.95
D HR [bpm] – 0.9 ± 4.4 – – –0.01 ± 3.5 – 0.29 
Data are means ± standard deviation.
0
1
2
3
4
5
6
7
8
9
10
Physical
Social
Emotional
Global
BSL 3 MFU
*P < 0.05 vs. BSL
4.7 4.9 5.1 5.2 5.4 5.5 5.34.9
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of pressor and cardiac responses to mental stress 
were markedly reduced and reached one-fourth and 
one-third of the values obtained in patients with 
untreated essential hypertension [31]. Similarly, 
CV reactivity to hand-grip and cold pressor tests 
were substantially attenuated in HFrEF compared 
to hypertensive patients likely as a result of higher 
sympathetic drive in the failing heart compared to 
essential hypertension. 
Notably, mental arithmetic stress per se has 
been shown to induce threefold increases in NA 
release from sympathetic nerves to the heart in 
essential hypertension [48] and to cause silent 
myocardial ischemia in patients with CAD [49]. 
This observation indicates that repetitive expo-
sure to psychological factors is likely to cause 
silent damage to the heart, adversely affecting the 
CV system (i.e. alterations in myocardial oxygen 
demand and supply), thereby predisposing acute 
adverse events. The present study found sig-
nificant increases in BP and HR responses to all 
laboratory stressors with a greater CV reactivity 
to mental stress than isometric and cold pressor 
tests. Moreover, in this study acute SLOWB sig-
nificantly reduced BP and HR responses to acute 
mental stress, whereas a 3-month therapy with 
SLOWB led to a further and pronounced reduction 
in CV responses to mental stress in patients with 
severe HFrEF that is beyond improvements in 
oxygen saturation, functional performance levels, 
cardiorespiratory capacity and HR variability [29]. 
Whether the incremental benefit on stress reduc-
tion achieved with SLOWB is likely to translate to 
improved outcomes in HFrEF needs to be investi-
gated in larger clinical trials.  
A further important finding observed after 3 
months of SLOWB was an improvement in health-
related QoL including mental, physical, social and 
global domains. This could be of clinical relevance 
given the high incidence of depression in HF and 
its adverse contribution to the long-term prognosis. 
The current management of HF predominantly 
aims at reducing symptoms of hypervolemia and 
arrhythmia with the subsequent reduction in hospi-
talization rates [4], whereas the mental health com-
ponent is often ignored in clinical practise, mostly 
due to the lack of the validity and significance of 
QoL assessment methods. Recently, it has been 
highlighted that data documenting effects of thera-
peutic and behavioural interventions on prognostic 
parameters, exercise performance, functional 
capacity and psychological status in advance HF 
are scarce [3]. Of note, the psychological care is 
not available for the vast majority of HF patients 
and is rather limited to antidepressant therapy [4], 
indicating an unmet need for patient participation 
in behavioral therapy to regain control of the dis-
ease and manage breathing rate. In this context, 
the present findings support the notion that the 
assessment of QoL using MacNew questionnaires 
can be easily implemented in clinical practice for 
HF management, particularly in the absence of a 
professional psychotherapist. Certainly, SLOWB 
therapy is easy to use in home settings and a cost-
effective approach to be offered to HF patients to 
improve patient engagement in health care and 
associated QoL. 
It is noteworthy to mention that a substantial 
proportion of HF patients on optimal pharmaco-
logical and HF device therapies report subjective 
perceptions of dyspnoea in the absence of objec-
tive indications of hypervolemia. In this clinical 
scenario, SLOWB home training exerts beneficial 
effects in treating breathlessness. The present 
findings are supported by objective evidence docu-
menting long-term effectiveness of SLOWB home 
training in improving oxygen saturation, functional 
performance levels, cardiorespiratory function and 
slowing progression of the disease in patients with 
severe HFrEF [29]. 
Strengths of the present study include pre-
cise evaluations of acute and long-term effects 
of SLOWB on hemodynamic responses to labo-
ratory stressors in patients with severe HFrEF 
who received available treatment options as per 
ESC guidelines. Secondly, medication remained 
unchanged during the 3-month therapy of SLOWB 
home training, thereby eliminating potential con-
founding effects of drug therapy. Thirdly, all pa-
tients reached final breathing rate of 6 ± 1 breaths/
min at the end of the RESPeRATE® session and 
significantly reduced a spontaneous breathing rate 
at 3 months follow-up [29]. Fourthly, no patient 
presented with active stimulation during expo-
sure to laboratory tests and response dependent 
stimulation which might have affected results of the 
HR change under the stressors. Finally, no patient 
experienced worsening of HF or other events over 
the duration of the study indicating clinical benefits 
achieved with SLOWB therapy.
Limitations of the study
The limitations of the present study include 
a modest number of patients and the lack of a 
control group. However, this study was a logical 
continuation of previous clinical experience in 
patients with essential hypertension who under-
went a similar study protocol and could thereby 
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serve as controls. Moreover, the present study 
included patients with severe HFrEF who received 
evidence-based therapy for HF and still remain at 
high risk for HF decompensation, hospital readmis-
sion and HF-related mortality. While the possible 
occurrence of a potential “learning effect”, with 
repetition of applied stressor tests over time could 
be viewed as a limitation, it was previously shown 
that no changes in hemodynamics were observed 
in response to repeated mental or isometric tests 
without SLOWB therapy [31]. 
Conclusions
The present results indicate that even in 
the absence of other available treatment options, 
behavioural intervention such as SLOWB home 
training appears to have substantial impact on 
distress and health-related QoL in severe HFrEF 
on top of evidence-based HF management. These 
favourable benefits of SLOWB occurred in addition 
to improvements in cardiorespiratory capacity, 
functional performance levels, vagal activity and 
attenuation of HF progression. While this study 
involves patients with very severe HFrEF, it seems 
that SLOWB as an add-on therapy may provide 
beneficial effects on mental, social, physical and 
global components in all HF patients independent 
of HF etiology. Ideally these benefits  could be 
tested in further clinical studies. 
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